DNAJB6 Protein

DNAJB6 Protein (MRJ)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">DNAJB6 Protein</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>DNAJB6</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>DnaJ Heat Shock Protein Family Member B6</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>MRJ, HLJ1, DNAJB6</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O75186</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~38 kDa (isoform a), ~26 kDa (isoform b)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Hsp40/DnaJ family (subfamily B)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain ([neurons](/entities/neurons), glia), muscle, heart, widespread peripheral tissues</td>
</tr>
<tr>
<td class="label">Cellular Location</td>
<td>Cytoplasm, nucleus (isoform-dependent)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/huntington's-disease" style="color:#ef9a9a">Huntington's disease</a>, <a href="/wiki/lgmdd1" style="color:#ef9a9a">LGMDD1</a>, <a href="/wiki/myofibrillar-myopathy" style="color:#ef9a9a">Myofibrillar Myopathy</a>, <a href="/wiki/parkinson's-disease" style="color:#ef9a9a">Parkinson's disease</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-c9486869" style="color:#ce93d8" title="Score: 0.55">HSP70

...

DNAJB6 Protein (MRJ)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">DNAJB6 Protein</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>DNAJB6</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>DnaJ Heat Shock Protein Family Member B6</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>MRJ, HLJ1, DNAJB6</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O75186</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~38 kDa (isoform a), ~26 kDa (isoform b)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Hsp40/DnaJ family (subfamily B)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain ([neurons](/entities/neurons), glia), muscle, heart, widespread peripheral tissues</td>
</tr>
<tr>
<td class="label">Cellular Location</td>
<td>Cytoplasm, nucleus (isoform-dependent)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/huntington's-disease" style="color:#ef9a9a">Huntington's disease</a>, <a href="/wiki/lgmdd1" style="color:#ef9a9a">LGMDD1</a>, <a href="/wiki/myofibrillar-myopathy" style="color:#ef9a9a">Myofibrillar Myopathy</a>, <a href="/wiki/parkinson's-disease" style="color:#ef9a9a">Parkinson's disease</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-c9486869" style="color:#ce93d8" title="Score: 0.55">HSP70 Co-chaperone DNAJB6 Universal Cros...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">44 edges</a></td>
</tr>
</table>

Introduction

Dnajb6 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

DNAJB6 (DNAJ Heat Shock Protein Family Member B6), also known as MRJ (Mouse RnaJ homolog), is a member of the Hsp40/DnaJ family of molecular chaperones that plays critical roles in protein quality control, aggregation prevention, and cellular protection against proteotoxic stress. Unlike classical Hsp40s, DNAJB6 possesses unique structural features and client binding properties that make it particularly effective at preventing amyloid fiber formation. The protein has emerged as a key therapeutic target for neurodegenerative diseases characterized by protein misfolding and aggregation, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. [@kakkar2014]

Protein Information

Molecular Function

Chaperone Activity

DNAJB6 functions as a molecular chaperone through multiple mechanisms: [@gao2021]

• J Domain Activity: The N-terminal J domain (approximately 70 amino acids) recruits and stimulates Hsp70 ATPase activity, facilitating the Hsp70-DnaJB6 collaborative cycle for protein folding and disaggregation [1].
• Client Binding: The C-terminal client-binding domain (CTD) directly interacts with misfolded and aggregation-prone proteins, recognizing hydrophobic patches and structured aggregation nuclei [2].
• Aggregation Prevention: DNAJB6 sequesters aggregation-prone proteins in reversible complexes, preventing the nucleation and elongation of amyloid fibrils through a "holdase" mechanism distinct from classical refolding chaperones [3].
• Hsp70 Cooperation: DNAJB6 works synergistically with Hsp70 family members (HSPA1A, HSPA8) in a coordinated hand-off mechanism where initial capture by DNAJB6 is followed by Hsp70-mediated refolding or targeting to degradation pathways [4].

Regulation of Protein Quality Control

• [Autophagy](/entities/autophagy) Modulation: DNAJB6 interacts with autophagy receptors and regulates selective autophagy of aggregation-prone proteins through LC3-interacting regions (LIRs) [5].
• Proteasome Targeting: The chaperone facilitates ubiquitination of misfolded proteins and targets them to the 26S proteasome for degradation [6].
• Stress Response: DNAJB6 expression is upregulated by heat shock and other proteotoxic stresses through HSF1-dependent transcription [7].

Structure-Function Relationships

Domain Architecture

The multi-domain structure of DNAJB6 enables its specialized aggregation-prevention activity: [@brehme2014]

J Domain (Residues 1-70): Contains the highly conserved HPD motif essential for Hsp70 interaction. This domain recruits Hsp70 and stimulates its ATPase activity [8].

Gly/Phe-Rich Region (Residues 71-170): This flexible linker region contains multiple phenylalanine and glycine residues that may contribute to client protein recognition and self-association properties [9].

C-terminal Client-Binding Domain (CTD, Residues 171-324): The signature feature of DNAJB6 distinguishes it from other DnaJ proteins. This domain forms a stable dimerization unit that creates a "clamp" for client protein binding [10].

Isoforms

DNAJB6 generates multiple isoforms through alternative splicing: [@winner2011]

• Isoform a (full-length, 324 aa): Contains all domains, primarily cytoplasmic
• Isoform b (isoform 2, 242 aa): Lacks part of the CTD, shows altered client binding
• Isoform c/d: Minor variants with tissue-specific expression

Disease Associations

Alzheimer's Disease

DNAJB6 plays multiple protective roles in Alzheimer's disease pathogenesis: [@satake2009]

• [Tau](/proteins/tau) Pathology: DNAJB6 directly interacts with hyperphosphorylated [tau](/proteins/tau) and prevents its aggregation into neurofibrillary tangles. Studies show reduced DNAJB6 expression in AD brain tissue correlates with increased [tau](/proteins/tau) pathology [11].
• Amyloid-β Handling: The chaperone assists in clearance of Aβ42 oligomers and may enhance microglial phagocytosis of [Aβ](/proteins/amyloid-beta) plaques through autophagy regulation [12].
• Synaptic Protection: DNAJB6 preserves synaptic protein homeostasis and protects against Aβ-induced synaptic dysfunction [13].
• Therapeutic Potential: Small molecules that enhance DNAJB6 expression or activity represent a novel therapeutic approach for AD [14].

Parkinson's Disease

• α-Synuclein Aggregation: DNAJB6 is one of the most potent endogenous inhibitors of α-synuclein fibrillization. It binds to the NAC region of α-syn and prevents both nucleation and fibril elongation [15].
• Genetic Links: GWAS studies have identified DNAJB6 variants associated with increased PD risk, suggesting it may act as a disease modifier [16].
• Dopaminergic Neuron Protection: DNAJB6 overexpression protects dopaminergic neurons from MPTP-induced toxicity in models of PD [17].
• LRRK2 Interaction: DNAJB6 interacts with pathogenic LRRK2 mutants and may modulate LRRK2-associated neurodegeneration [18].

Huntington's Disease

• Polyglutamine Aggregation: DNAJB6 is exceptionally effective at preventing polyglutamine (polyQ) expansion protein aggregation, the hallmark of Huntington's disease [19].
• [Huntingtin](/proteins/huntingtin-protein) Clearance: The chaperone facilitates autophagy-mediated clearance of mutant [huntingtin](genes/htt) fragments and reduces toxicity in cellular and mouse models [20].
• Therapeutic Development: DNAJB6-based gene therapy approaches are being developed for HD treatment [21].

Amyotrophic Lateral Sclerosis (ALS)

• [TDP-43](/proteins/tdp-43) Pathology: DNAJB6 may counteract [TDP-43](/mechanisms/tdp-43-proteinopathy) aggregation, a central feature of ALS pathology. Reduced DNAJB6 is observed in ALS patient spinal cord [22].
• SOD1 Handling: DNAJB6 assists in proper folding and clearance of mutant SOD1, which forms aggregates in some familial ALS cases [23].
• C9orf72关联: Interactions between DNAJB6 and dipeptide repeat proteins from [C9orf72](/entities/c9orf72) expansions suggest potential therapeutic applications [24].

Muscular Dystrophies

• Limb-Girdle Muscular Dystrophy Type D1 (LGMDD1): Dominant mutations in DNAJB6 cause LGMDD1, characterized by progressive weakness of pelvic and shoulder girdle muscles. The mutations impair the chaperone's anti-aggregation activity [25].
• Muscle Protein Homeostasis: DNAJB6 is essential for maintaining skeletal muscle protein quality control, particularly during exercise-induced stress [26].

Cancer

While DNAJB6 is primarily studied in neurodegeneration, it also has cancer-relevant functions: [@dong2016]

• Tumor suppressor activity in certain cancers
• Regulation of cell cycle progression
• Potential biomarker for cancer prognosis

Therapeutic Implications

Small Molecule Approaches

• Chaperone Enhancers: Compounds that increase DNAJB6 expression (e.g., through HSF1 activation) or enhance its client-binding affinity [27]
• Aggregation Inhibitors: Combination approaches using DNAJB6 activity enhancers with direct aggregation inhibitors [28]

Gene Therapy

• AAV-Mediated Delivery: Adeno-associated virus vectors engineered to deliver DNAJB6 to brain regions affected by neurodegeneration [29]
• CRISPR Activation: CRISPR-based approaches to upregulate endogenous DNAJB6 expression [30]

Protein-Based Therapeutics

• Recombinant Chaperone Delivery: Engineering DNAJB6 variants with enhanced [blood-brain barrier](/entities/blood-brain-barrier) penetration [31]
• Fusion Proteins: Creating DNAJB6-based fusion proteins with improved delivery properties [32]

Research Directions

Basic Research Priorities

Structural Studies: High-resolution structures of DNAJB6-client complexes to enable rational drug design

Mechanism Elucidation: Detailed characterization of the hand-off between DNAJB6 and Hsp70

Isoform-Specific Functions: Understanding differential roles of DNAJB6 isoforms in disease

Clinical Development

Biomarker Development: DNAJB6 levels as a biomarker for disease progression or treatment response

Patient Stratification: Genetic variants in DNAJB6 as predictors of therapeutic response

Combination Therapies: Optimal combinations with other chaperones or aggregation inhibitors

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Huntington's Disease](/diseases/huntington-disease)
• [ALS](/diseases/als)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Tau Protein](/proteins/tau)
• [Huntingtin Protein](/proteins/huntingtin-protein)
• [Protein Folding Pathway](/mechanisms/protein-folding-pathway)
• [Chaperone Proteins](/entities/chaperones)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy-lysosome-neurodegeneration)mechanisms/autophagy-lysosomal-pathway)
• [Hsp70 Family](/entities/hsp70-family)
• [TDP-43 Pathology](/mechanisms/tdp-43-pathology)

Background

The study of Dnajb6 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@markham2019]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@lotz2013]

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Additional evidence sources: [@chen2015] [@calamini2011] [@liu2019] [@gifondorwa2012] [@zhang2018] [@sarparanta2012] [@drake2016] [@neef2010] [@cohen2012] [@flagmeier2020] [@bakowska2021] [@bandyopadhyay2018] [@balana2021]

References

[Chuang JZ, et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29567863/)

[Kakkar V, et al, (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25224402/)

[Hageman J, et al, (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20094033/)

[Zhang Y, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32265640/)

[Dec E, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32027638/)

[Menzies FM, et al, (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26123493/)

[Harms MB, et al, (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23540573/)

[Choi SI, et al, (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23530044/)

[Boelens WC, et al, (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24715654/)

[Szutorisz H, et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/30518865/)

[Chen Y, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31187234/)

[Fontaine SN, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32880976/)

[Gao X, et al, (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33838382/)

[Brehme M, et al, (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25224573/)

[Winner B, et al, (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21585657/)

[Satake W, et al, (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19898480/)

[Dong XX, et al, (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27799073/)

[Markham A, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31504245/)

[Lotz GP, et al, (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23528880/)

[Chen Y, et al, (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26123492/)

[Calamini B, et al, (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/22198730/)

[Liu HJ, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31796118/)

[Gifondorwa DJ, et al, (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22487428/)

[Zhang Y, et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29590609/)

[Sarparanta J, et al, (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22818854/)

[Drake JC, et al, (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27335313/)

[Neef DW, et al, (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20944662/)

[Cohen E, et al, (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22306604/)

[Flagmeier P, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32376123/)

[Bakowska K, et al, (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33478756/)

[Bandyopadhyay S, et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29154852/)

[Balana AT, et al, (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33462395/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor](/hypothesis/h-c9486869) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DNAJB6